Mechelen, Belgium-based Galapagos NV has announced a new two-year target discovery collaboration between Janssen Pharmaceutica, a Johnson & Johnson company, and BioFocus DPI, Galapagos' service division, in the field of oncology. BioFocus will apply Galapagos' proprietary adenoviral platform to identify novel drug targets for the development of cancer therapies.
The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus will perform assay development, screening of the SilenceSelect and FLeXSelect adenoviral libraries, and target validation. Target discovery in cutting edge in vitro assays may provide novel drug targets for cancer areas with an unmet medical need. BioFocus receives an upfront payment of 2.9 million euros ($4.2 million). In total, BioFocus may receive additional research, acceptance, license and development fees of up to 7.6 million euros should certain pre-determined criteria be achieved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze